Clonal hematopoiesis and thrombosis risk—what are research and clinical gaps?
Open Access
- 9 May 2026
- journal article
- review article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (4) , 106650
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trialsNature Medicine, 2024
- The clonal hematopoiesis mutation Jak2 aggravates endothelial injury and thrombosis in arteries with erosion-like intimasInternational Journal of Cardiology, 2024
- Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular DiseaseJACC, 2023
- TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic diseaseNature Cardiovascular Research, 2023
- TET2-Driven Clonal Hematopoiesis and Response to CanakinumabJAMA Cardiology, 2022
- The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesisNature, 2021
- Inherited causes of clonal haematopoiesis in 97,691 whole genomesNature, 2020
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseaseNew England Journal of Medicine, 2017
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesNew England Journal of Medicine, 2014